Ausgabe 2/2013
Inhalt (28 Artikel)
Low serum testosterone levels are predictive of prostate cancer
Luigi Mearini, Alessandro Zucchi, Elisabetta Nunzi, Tommaso Villirillo, Vittorio Bini, Massimo Porena
Circulating free testosterone is an independent predictor of advanced disease in patients with clinically localized prostate cancer
Thomas Schnoeller, Florian Jentzmik, Ludwig Rinnab, Marcus V. Cronauer, Ilija Damjanoski, Friedemann Zengerling, Andreas Al Ghazal, Mark Schrader, Andres J. Schrader
Serum testosterone plays an important role in the metastatic ability of castration resistant prostate cancer
Tim M. van der Sluis, Irene V. Bijnsdorp, John J. L. Jacobs, Eric J. H. Meuleman, Lawrence Rozendaal, Albert A. Geldof, R. Jeroen A. van Moorselaar, André N. Vis
Circulating sex steroids and prostate cancer: introducing the time-dependency theory
Andrea Salonia, Firas Abdollah, Umberto Capitanio, Nazareno Suardi, Andrea Gallina, Giulia Castagna, Maria Chiara Clementi, Alberto Briganti, Patrizio Rigatti, Francesco Montorsi
Preoperative sex steroids are significant predictors of early biochemical recurrence after radical prostatectomy
Andrea Salonia, Firas Abdollah, Umberto Capitanio, Andrea Gallina, Nazareno Suardi, Alberto Briganti, Giuseppe Zanni, Matteo Ferrari, Fabio Castiglione, Maria Chiara Clementi, Patrizio Rigatti, Francesco Montorsi
Vitamin D receptor gene variants and clinical outcomes after androgen-deprivation therapy for prostate cancer
Jiunn-Bey Pao, Ying-Pi Yang, Chun-Nung Huang, Shu-Pin Huang, Tzyh-Chyuan Hour, Ta-Yuan Chang, Yu-Hsuan Lan, Te-Ling Lu, Hong-Zin Lee, Shin-Hun Juang, Chao-Yuan Huang, Bo-Ying Bao
Patients with prostate cancer treated by ADT have significantly higher fibrinogenemia than healthy control
Stanislav Ziaran, Frederico Manuel Goncalves, Jan Breza Sr
Long-term PSA-free survival and castration-free survival with delayed antiandrogen therapy in patients with one versus two or more positive nodes at prostatectomy
Michele Lodde, Louis Lacombe, Angelo Naselli, Paolo Puppo, Michael Mian, Yves Fradet
Parameters derived from the postoperative decline in ultrasensitive PSA improve the prediction of radical prostatectomy outcome
Stepan Vesely, Ladislav Jarolim, Marek Schmidt, Ivo Minarik, Pavel Dusek, Marko Babjuk
Diagnostic significance of [−2]pro-PSA and prostate dimension-adjusted PSA-related indices in men with total PSA in the 2.0–10.0 ng/mL range
Kazuto Ito, Mai Miyakubo, Yoshitaka Sekine, Hidekazu Koike, Hiroshi Matsui, Yasuhiro Shibata, Kazuhiro Suzuki
Association between percent-free prostate-specific antigen and glomerular filtration rate in transrectal ultrasound-guided biopsy-proven patients with prostate-specific antigen levels ranging from 4 to 10 ng/ml
Jae Heon Kim, Ji Sung Shim, Jae Hyun Bae, Hong Seok Park, Du Geon Moon, Soon-Sun Kwon, Jae Young Park
Impact of total PSA, PSA doubling time and PSA velocity on detection rates of 11C-Choline positron emission tomography in recurrent prostate cancer
Maxim Rybalov, Anthonius J. Breeuwsma, Anna M. Leliveld, Jan Pruim, Rudi A. Dierckx, Igle J. de Jong
Potential therapeutic applications of phosphodiesterase inhibition in prostate cancer
Thomas K. Hamilton, Nianping Hu, Klodiana Kolomitro, Erin N. Bell, Donald H. Maurice, Charles H. Graham, D. Robert Siemens
Intratumoral acetic acid injection eradicates human prostate cancer tumors in a murine model
Jasneet Singh Bhullar, Gokulakkrishna Subhas, Sushant Chaudhary, Boris Silberberg, Jacqueline Tilak, Milessa Decker, Vijay K. Mittal
A switch from GnRH agonist to GnRH antagonist in castration-resistant prostate cancer patients leads to a low response rate on PSA
Alexandra Masson-Lecomte, Laurent Guy, Philippe Pedron, Franck Bruyere, Morgan Rouprêt, Bonaventure Nsabimbona, Mickael Dahan, Patrice Hoffman, Laurent Salomon, Dimitri Vordos, Andras Hoznek, Philippe Le Corvoisier, Pierrick Morel, Claude Abbou, Alexandre de la Taille
Altered expression of farnesyl pyrophosphate synthase in prostate cancer: evidence for a role of the mevalonate pathway in disease progression?
Tilman Todenhöfer, Jörg Hennenlotter, Ursula Kühs, Valentina Gerber, Georgios Gakis, Ulrich Vogel, Stefan Aufderklamm, Axel Merseburger, Judith Knapp, Arnulf Stenzl, Christian Schwentner
Galectin-3 expression in prostate cancer and benign prostate tissues: correlation with biochemical recurrence
Judith S. Knapp, Soum D. Lokeshwar, Ulrich Vogel, Jörg Hennenlotter, Christian Schwentner, Mario W. Kramer, Arnulf Stenzl, Axel S. Merseburger
Association of legumain expression pattern with prostate cancer invasiveness and aggressiveness
Yoshio Ohno, Jun Nakashima, Miki Izumi, Makoto Ohori, Takeshi Hashimoto, Masaaki Tachibana
When to perform bone scan in patients with newly diagnosed prostate cancer: external validation of a novel risk stratification tool
Cosimo De Nunzio, Costantino Leonardo, Giorgio Franco, Francesco Esperto, Aldo Brassetti, Giovanni Simonelli, Dino Dente, Carlo De Dominicis, Andrea Tubaro
Hemodynamic effects of orally administered delta-ALA during radical prostatectomy
Volker Eichhorn, Alexander Maerz, Georg Salomon, Irmgard F. Blanc, Daniel A. Reuter, Alwin E. Goetz
Prostatic peripheral nerve distribution may impact the functional outcome of nerve-sparing prostatectomy
B. Amend, J. Hennenlotter, U. Kuehs, I. Laible, A. Anastasiadis, D. Schilling, A. Stenzl, K. D. Sievert
Effect of dorsal vascular complex size on the recovery of continence after radical prostatectomy
Chang Wook Jeong, Jong Jin Oh, Seong Jin Jeong, Sung Kyu Hong, Seok-Soo Byun, Sung Il Hwang, Hak Jong Lee, Sang Eun Lee
Prospective comparison of scar-related satisfaction and quality of life after laparoscopic versus open radical prostatectomy: no differences from patients’ point of view
Nicolas Barry Delongchamps, Olivier Belas, Djillali Saighi, Marc Zerbib, Michaël Peyromaure
Impact of positive surgical margins on oncological outcome following laparoscopic radical prostatectomy (LRP): long-term results
Jonas Busch, Carsten Stephan, Annett Klutzny, Stefan Hinz, Carsten Kempkensteffen, Ergin Kilic, Michael Lein, Steffen Weikert, Kurt Miller, Ahmed Magheli
Patterns of outcome and toxicity after salvage prostatectomy, salvage cryosurgery and salvage brachytherapy for prostate cancer recurrences after radiation therapy: a multi-center experience and literature review
Max Peters, Maaike R. Moman, Henk G. van der Poel, Henk Vergunst, Igle Jan de Jong, Peter L. M. Vijverberg, Jan J. Battermann, Simon Horenblas, Marco van Vulpen
Prostate-specific antigen kinetics after I125-brachytherapy for prostate adenocarcinoma
Alessia Guarneri, Angela Botticella, Riccardo Ragona, Andrea Riccardo Filippi, Fernando Munoz, Giovanni Casetta, Paolo Gontero, Alessandro Tizzani, Umberto Ricardi
Pudendal nerve block in HDR-brachytherapy patients: do we really need general or regional anesthesia?
Marcus Schenck, Catarina Schenck, Herbert Rübben, Martin Stuschke, Tim Schneider, Andreas Eisenhardt, Roberto Rossi
Salvage radiotherapy in patients with persistently detectable PSA or PSA rising from an undetectable range after radical prostatectomy gives comparable results
Gunnar Lohm, Dirk Bottke, Basil Jamil, Kurt Miller, Konrad Neumann, Detlef Bartkowiak, Wolfgang Hinkelbein, Thomas Wiegel